Skip to main content
. 2020 Jan 24;11(2):164–183. doi: 10.1039/c9md00447e

Fig. 2. Chemical structures of the small molecule inhibitors (7–16) of PC with positive outcomes in phase I clinical trials, and capecitabine (17). Of note, the vorinostat (13) and capecitabine (17) combination phase I clinical trial showed an encouraging MoS of 1.1 year.34.

Fig. 2